Search the database for deliberate release of GM medicinal products
Displaying 1 - 3 of 3
|EU record number
|Company / Sponsor
|Only notified under the "contained use" procedure. Dossier submitted on 20/08/2018.
|A Phase I/II study of the safety and efficacy of a single dose of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells in subjects with severe sickle disease
|CRISPR Therapeutic AG
|Modified cells expressing Hemoglobin F (HbF)
|Only notified under the "contained use" procedure. Dossier submitted on 08/07/2010.
|An open-label, phase I, dose-escalation and safety study of two intramuscular injections at dose of 2.9 log or 4 log CCID50 of the recombinant HIV I clade B measles vaccine vector in healthy adults.
|Institut Pasteur - Paris
|Gag, Pol, Nef genes of HIV
|Evaluation of the safety of Feline Herpes Virus, bivalent deleted live vaccine, administered as intranasal vaccine to cats
|Pfizer, Animal Health Group
|gene for the env glycoprotein or gene for the gag protein of the Feline immunodeficiency virus (FIV)